A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ALPS
- Sponsors Astellas Pharma BV
- 10 Jun 2017 Biomarkers information updated
- 17 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Nov 2017.
- 17 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2017.